TAC1 Protein (Tachykinin Precursor 1)
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">TAC1 (Tachykinin Precursor 1) Protein</th>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Primary Ligand</td>
</tr>
<tr>
<td class="label">NK1R (TACR1)</td>
<td>Substance P</td>
</tr>
<tr>
<td class="label">NK2R (TACR2)</td>
<td>Neurokinin A</td>
</tr>
<tr>
<td class="label">NK3R (TACR3)</td>
<td>Neurokinin B</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">Aprepitant</td>
<td>AD</td>
</tr>
<tr>
<td class="label">NK1 antagonist</td>
<td>PD</td>
</tr>
<tr>
<td class="label">Substance P analog</td>
<td>MS</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">14 edges</a></td>
</tr>
</table>
Overview
TAC1 (Tachykinin Precursor 1) is a gene encoding preprotachykinin, the precursor protein for the tachykinin peptide family, including [Substance P](/entities/substance-p) (SP), [Neurokinin A](/entities/neurokinin-a) (NKA), neuropeptide K (NPK), and neuropeptide γ (NPγ)[@severini2002]. These peptides function as neurotransmitters and neuromodulators throughout the central and peripheral nervous systems, playing critical roles in pain transmission, neuroinflammation, and stress responses. The TAC1 gene and its encoded peptides have emerged as significant players in the pathophysiology of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and related disorders[@steinhoff2014].
The tachykinin system represents one of the oldest neuropeptide signaling systems in evolution, with conserved functions across species from amphibians to humans. In the mammalian brain, Substance P and Neurokinin A are expressed in distinct neuronal populations within the basal ganglia, cortex, hippocampus, and brainstem, where they modulate dopaminergic signaling, GABAergic transmission, and inflammatory responses[@chen2005].
Gene Structure and Alternative Splicing
The TAC1 gene is located on human chromosome 7q21-22 and spans approximately 9.5 kb. It consists of seven exons that undergo complex alternative splicing to generate multiple mRNA isoforms encoding distinct preprotachykinin variants[@euler2014]. The primary isoforms include:
- Preprotachykinin-A (PPT-A): Generates Substance P (SP, 11 amino acids), Neurokinin A (NKA, 10 amino acids), neuropeptide K (NPK, 36 amino acids), and neuropeptide γ (NPγ, 21 amino acids)
- Preprotachykinin-B (PPT-B): Generates Neurokinin B (NKB, 10 amino acids), encoded by the separate TAC3 gene
The expression of TAC1 is regulated by multiple transcription factors including AP-1, CREB, and NF-κB, allowing dynamic modulation in response to neuronal activity, stress, and inflammatory stimuli. Alternative promoter usage and exon skipping result in tissue-specific patterns of tachykinin peptide expression[@euler2014].
Protein Structure and Processing
Precursor Processing
The preprotachykinin precursor (approximately 15-17 kDa depending on isoform) undergoes post-translational processing in the secretory pathway to generate mature tachykinin peptides[@severini2002]:
Signal peptide cleavage: The N-terminal signal sequence is removed in the endoplasmic reticulum
Propeptide cleavage: Furin-like convertases cleave at dibasic residues (Lys-Arg, Arg-Arg) to release mature peptides
C-terminal amidation: The C-terminal glycine is amidated to produce the active peptide
Secretory granule packaging: Mature peptides are packaged into dense-core secretory vesiclesTachykinin Peptide Receptors
The biological effects of TAC1-derived peptides are mediated through three G protein-coupled receptors[@steinhoff2014]:
NK1R has the highest affinity for Substance P and is the primary receptor mediating central nervous system effects of tachykinins. Receptor activation triggers phospholipase C activation, generating inositol trisphosphate (IP3) and diacylglycerol (DAG), leading to intracellular calcium mobilization and protein kinase C activation[@steinhoff2014].
Normal Physiological Functions
Pain and Nociception
Substance P serves as a primary neurotransmitter in nociceptive (pain-sensing) primary afferent neurons. In the dorsal horn of the spinal cord, Substance P is released from central terminals of C-fibers to transmit pain signals to second-order neurons[@kramer1998]. NK1R activation on spinal neurons contributes to:
- Nociceptive transmission and central sensitization
- Neurogenic inflammation and plasma extravasation
- Modulation of opioid peptide release
- Induction of mast cell degranulation
The tachykinin system is thus a critical component of the pain processing axis and has been targeted for analgesic drug development.
Neurotransmission and Modulation
In the brain, TAC1-derived peptides function as neuromodulators rather than classical neurotransmitters[@saria1999]:
- Basal ganglia: Substance P is expressed in striatal medium spiny neurons and modulates dopaminergic signaling. The striatonigral and striatopallidal pathways contain Substance P that influences motor control.
- Hippocampus: NK1R activation modulates hippocampal synaptic plasticity, memory formation, and seizure threshold.
- Amygdala and hypothalamus: Tachykinins participate in stress responses, anxiety, and emotional processing.
- Raphe nuclei: Substance P-containing neurons project to spinal cord pain transmission sites.
Immune Modulation
Substance P exerts potent pro-inflammatory effects through NK1R on immune cells[@khan2018]:
- Microglia: Activation of microglial NK1R triggers release of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) and chemokines
- Astrocytes: Tachykinin signaling promotes astrocyte reactivity and neuroinflammation
- Peripheral immune cells: Substance P enhances neutrophil migration, macrophage phagocytosis, and T-cell activation
Role in Neurodegenerative Diseases
Alzheimer's Disease
Substance P and NK1R are altered in Alzheimer's disease brains, with implications for both amyloid pathology and neuroinflammation[@pichon2014][@hall2016][@riemer2016]:
Amyloid-Tachykinin Interactions:
- Substance P can bind to amyloid-β (Aβ) peptides and influence their aggregation kinetics
- NK1R activation promotes amyloid precursor protein (APP) processing toward amyloidogenic Aβ production
- Aβ exposure upregulates TAC1 expression in neurons and glia, creating a feed-forward inflammatory loop
Neuroinflammation:
- Elevated Substance P levels in AD brain correlate with neurofibrillary tangle burden[@riemer2016]
- NK1R-mediated microglial activation contributes to chronic neuroinflammation
- Substance P enhances tau phosphorylation through NK1R-GSK3β signaling
Therapeutic Implications:
- NK1R antagonists reduce Aβ-induced neurotoxicity in cellular models
- Preclinical studies show improved cognitive performance with NK1R blockade
- Substance P imaging ligands detect neuroinflammation in living AD patients[@martinez2024]
Parkinson's Disease
The tachykinin system is intimately connected with dopaminergic neuron degeneration in Parkinson's disease[@behbehani1995][@toth2010]:
Basal Ganglia Dysfunction:
- Substance P is highly expressed in substantia nigra pars compacta (SNc) dopaminergic neurons
- NK1R is present on dopaminergic neurons and modulates dopamine release
- Loss of Substance P-containing neurons contributes to motor dysfunction
Neuroinflammation:
- Elevated CSF levels of Substance P reported in PD patients[@toth2010]
- NK1R activation on microglia promotes dopaminergic neuron death
- Tachykinin-mediated inflammation exacerbates α-synuclein pathology
Therapeutic Strategies:
- NK1R antagonists protect dopaminergic neurons in experimental PD models[@liu2019][@zhang2023]
- NK1R modulation reduces microglial activation and improves motor function
- TAC1 gene expression analysis reveals dysregulation in PD substantia nigra[@walker2024]
Other Neurodegenerative Conditions
Amyotrophic Lateral Sclerosis (ALS):
- Elevated Substance P in spinal cord and CSF of ALS patients
- NK1R contributes to motor neuron excitotoxicity
- NK1R antagonists show protective effects in SOD1 mouse models
Multiple Sclerosis (MS):
- Substance P promotes demyelination and immune cell infiltration
- NK1R blockade reduces disease severity in experimental autoimmune encephalomyelitis
- Tachykinin system correlates with disease progression
Huntington's Disease:
- TAC1 expression altered in striatal neurons
- NK1R antagonists ameliorate behavioral deficits in HD models
- Substance P modulates GABAergic signaling in the striatum
Molecular Mechanisms in Neurodegeneration
Signaling Pathways
NK1R activation triggers multiple intracellular signaling cascades relevant to neurodegeneration[@khan2018][@nielsen2020]:
Mermaid diagram (expand to render)
Neuroinflammation
Substance P promotes neuroinflammation through multiple mechanisms[@khan2018][@nielsen2020]:
Microglial activation: NK1R on microglia triggers NADPH oxidase activation and ROS production
Cytokine release: IL-1β, TNF-α, and IL-6 release from activated glia
Blood-brain barrier: NK1R activation increases BBB permeability
T-cell infiltration: Enhanced immune cell trafficking into CNSExcitotoxicity
Tachykinin signaling can contribute to excitotoxic neuronal death:
- NK1R activation increases glutamate release from presynaptic terminals
- Enhanced NMDA receptor phosphorylation and function
- Calcium dysregulation and mitochondrial dysfunction
Therapeutic Targeting
NK1 Receptor Antagonists
The tachykinin system has been targeted for drug development with NK1R antagonists[@kramer1998][@hall2016]:
Clinical Development:
- Aprepitant (Emend®): FDA-approved antiemetic, crosses BBB
- Fosaprepitant: Prodrug of aprepitant
- L-759274: Advanced NK1 antagonist for CNS disorders
Neurodegeneration Applications:
- Reduced neuroinflammation in AD/PD models
- Decreased microglial activation
- Improved cognitive and motor function in preclinical studies
Clinical Trials
Challenges and Future Directions
- Blood-brain barrier penetration of NK1 antagonists
- Receptor subtype selectivity (NK1 vs. NK2/NK3)
- Timing of intervention in disease progression
- Combination therapies targeting multiple neuroinflammatory pathways
Biomarker Potential
Tachykinin peptides show promise as biomarkers for neurodegenerative disease[@chen2022][@martinez2024]:
- CSF Substance P: Elevated in PD, AD, and ALS
- CSF Neurokinin A: Correlates with disease severity
- Imaging ligands: NK1R PET tracers in development
Research Methods
Detection Techniques
- Immunohistochemistry: NK1R and Substance P localization in brain tissue
- ELISA: Quantitation of peptide levels in CSF and plasma
- RT-PCR: TAC1 mRNA expression analysis
- PET imaging: NK1R binding in living brain (emerging)
- Single-cell RNA-seq: Cellular expression patterns[@walker2024]
Model Systems
- In vitro: Primary neuron and glial cultures, iPSC-derived neurons
- In vivo: Mouse models with genetic deletion of TAC1 or TACR1
- Transgenic: APP/PS1 and α-synuclein transgenic mice
Cross-Links
- [TAC1 Gene](/genes/tac1)
- [Substance P](/entities/substance-p)
- [Neurokinin A](/entities/neurokinin-a)
- [NK1 Receptor](/entities/nk1-receptor)
- [Tachykinin Signaling Pathway](/mechanisms/tachykinin-signaling)
- [Neuroinflammation Mechanisms](/mechanisms/neuroinflammation)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Microglial Activation](/mechanisms/microglial-activation)
References
[Behbehani, The role of substance P in the pathophysiology of Parkinson's disease (1995)](https://pubmed.ncbi.nlm.nih.gov/7566391/)
[Euler et al., Alternative splicing of the TAC1 gene (2014)](https://pubmed.ncbi.nlm.nih.gov/24837663/)
[Kramer et al., A placebo-controlled trial of L-759274 (1998)](https://pubmed.ncbi.nlm.nih.gov/9821538/)
[Saria, The tachykinin NK1 receptor in the brain (1999)](https://pubmed.ncbi.nlm.nih.gov/10552389/)
[Mantyh et al., Substance P receptor binding sites in the brain (2002)](https://pubmed.ncbi.nlm.nih.gov/11854539/)
[Töth et al., Substance P in CSF of PD patients (2010)](https://pubmed.ncbi.nlm.nih.gov/20674582/)
[Chen et al., Tachykinin-containing neurons in the basal forebrain (2005)](https://pubmed.ncbi.nlm.nih.gov/15690379/)
[Severini et al., The tachykinin peptide family (2002)](https://pubmed.ncbi.nlm.nih.gov/12417552/)
[Steinhoff et al., Tachykinins and their receptors (2014)](https://pubmed.ncbi.nlm.nih.gov/25444413/)
[Pichon et al., Substance P and neuroinflammation in AD (2014)](https://pubmed.ncbi.nlm.nih.gov/24718957/)
[Hall et al., Tachykinin receptor antagonists for AD (2016)](https://pubmed.ncbi.nlm.nih.gov/27079729/)
[Riemer et al., Substance P levels correlate with tau pathology (2016)](https://pubmed.ncbi.nlm.nih.gov/27524684/)
[Khan et al., Tachykinin signaling in neuroinflammation (2018)](https://pubmed.ncbi.nlm.nih.gov/29859518/)
[Liu et al., NK1 receptor and alpha-synuclein aggregation (2019)](https://pubmed.ncbi.nlm.nih.gov/30869125/)
[Nielsen et al., Substance P modulates microglial phagocytosis (2020)](https://pubmed.ncbi.nlm.nih.gov/32442755/)
[Warner et al., Tachykinin dysfunction in PD striatum (2021)](https://pubmed.ncbi.nlm.nih.gov/34015127/)
[Chen et al., TAC1-derived peptides as biomarkers (2022)](https://pubmed.ncbi.nlm.nih.gov/35959274/)
[Zhang et al., Neuroprotective effects of NK1 modulation (2023)](https://pubmed.ncbi.nlm.nih.gov/36849012/)
[Walker et al., Single-cell analysis of tachykinin expression (2024)](https://pubmed.ncbi.nlm.nih.gov/38340256/)
[Martinez et al., Substance P receptor imaging in patients (2024)](https://pubmed.ncbi.nlm.nih.gov/38472391/)